Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Blackcat that’s helpful.
https://docs.google.com/forms/d/e/1FAIpQLScPO1DbwWepLBCNhlPpiq1_jnaMGYwqzaXD-k_ZmvIft0dBMQ/viewform
This might help
When I wrote back about why I was disinvited, I got the following reply from Faezeh Chizari, CIR
Investor Relations
Thank you for contacting CAG regarding our appointment by Avacta. We are being employed to engage on the company’s behalf with the PCB, wealth manager and smaller institutional investor segment that we specialise in. The meetings that we organise are with this investor base and only with regulated entities.
Avacta will be expanding their investor relations programme into other areas, including private investors, later in the year and there will be opportunities for you to hear directly from the company as a result. ..
So the big organisations get information before the general public. That seems a bit unfair. I assume that the important RNSs we are waiting for so eagerly will arrive before the 2nd Feb ...
Keep patient and hold .. or top if you have any more spare funds
They are definitely more proactive ..
No more to add to the post .. it offered different choices
I would like a virtual 1:1 meeting
I would like to attend a virtual group meeting (2nd February @ 10.30am)
I'm interested in this company, but unable to make the dates/will pass this time
I'm not interested in this company
This invite is for institutional investors only. I had an invitation, but when I wrote back and said thank you, I was then disinvited !!!
Black Cat thanks for sharing. Your post looks to end part way through a sentence. Can you please post the rest of the invitation, assuming there is more? It looks as if there was more regarding diagnostics. Thanks
They also make comments on the therapeutics side, where they are " already begun to build the pipeline on other drugs, including Velcade ($1.2bn sales) and Paclitaxel ($2.96bn sales). " and regarding AVA6000 they state they "started dosing their first patients and currently at a stage to test safety and tolerability."
For these kind of meetings, they will have to show topline data of the safety and tolerability. They must be confident of the results so far.
Now thus us an interesting statement...are they saying the Covid LFT is just the start and they are a) going to improve it which is what they are doing right now and/or b) they will be looking to develop it for other viruses/diagnostic applications.
'The diagnostic division utilizes the Affirmer platform to develop diagnostic tests, e.g., Antigen Lateral Flow test. Following the strong shift in the diagnostics market towards decentralized testing and health monitoring devices, the division now focuses more on product development.'
thanks. Anyone on this BB going, who could share impression of the meeting etc. Be cool to know.
Avacta (AVCT, £193m Mkt Cap) | 2nd-4th February
**For professional investors only** We are organising an introduction to Avacta roadshow with CEO, Alistair Smith and CFO, Tony Gardiner on the 2nd-4th February. Avacta is an AIM-listed clinical stage oncology company that focuses on developing cancer therapies and diagnostics based on its Affimer and preCISION platforms. The Therapeutics division develops novel cancer immunotherapies combining its two proprietary platforms. The pre|CISION targeted chemotherapy platform releases active chemotherapy directly in the tumour, limiting systemic exposure and side effects associated with many commonly used cancer treatments. The first drug candidate is AVA6000 pro-Doxorubicin, a targeted form of the standard-of-care Doxorubicin which is a $1bn generic drug that is limited by its severe cardiotoxicity issues. With pro-Doxorubicin that is developed through the pre|CISION platform, the drug performance will increase dramatically with more effectiveness on the tumour and a significant reduction in cardiotoxicity. They have recently started dosing their first patients and currently at a stage to test safety and tolerability. The pre|CISION method can be applied to a range of other chemotherapies in a market worth $56.6B with CAGR of 11.50% and the company has already begun to build the pipeline on other drugs, including Velcade ($1.2bn sales) and Paclitaxel ($2.96bn sales). The diagnostic division utilizes the Affirmer platform to develop diagnostic tests, e.g., Antigen Lateral Flow test. Following the strong shift in the diagnostics market towards decentralized testing and health monitoring devices, the division now focuses more on product development. The Affimer platform is a novel class of biotherapeutic based on naturally occurring human protein which is an alternative to antibodies. The platform benefits from a strong competitive advantage as it is designed to address many of the negative performance issues, principally the time taken, reliance on animal`s immune response, poor specificity, size, and cost...